George Laliotis, Translational Medicine Lead of GU Oncologist at shared a post by JAMA Oncology on X, adding:
“Check our latest work.
Peri-operative FOLFIRINOX improved outcomes in patients with pancreatic cancer. ctDNA detection after surgery by Signatera was highly predictive of post-surgery outcomes. Promising data that support the integration of ctDNA in pancreatic cancer care management.”
Quoting the post by JAMA Oncology:
“Peri-operative modified FOLFIRINOX was safe and effective, with a clinically meaningful improvement in survival compared with historical controls.”
Visit the article website.
Source: George Laliotis/X and JAMA Oncology/X